



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

May 12, 2020

SENT VIA EMAIL

Allison Lucas
Siri & Glimstad
200 Park Ave
17th Floor
New York, NY 10166
foia@sirillp.com

Dear Ms. Lucas:

This letter is regarding to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of February 14, 2020, assigned #20-00631-FOIA, seeking:

“...an email enterprise search utilizing the following criteria:

Date range for the search:	August 1, 2019 to August 31, 2019
Individual(s) whose email account should be searched:	Frank DeStefano (fxd1@cdc.gov)
Limit search to emails with the following term in the subject line and/or body of the email:	London Vaccine

We located 46 pages of responsive records (35 pages released in full or part; 11 pages withheld in full). After a careful review of these pages, some information was withheld from release pursuant to 5 U.S.C. §552 Exemption 5 and 6.

Exemption 5 protects inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency. Exemption 5 therefore incorporates the privileges that protect materials from discovery in litigation, including the deliberative process, attorney work-product, and attorney-client privileges. Information withheld under this exemption was protected under the deliberative process privilege. The deliberative process privilege protects the decision-making process of government agencies. The deliberative process privilege protects materials that are both predecisional and deliberative. The materials that have been withheld under the deliberative process privilege of Exemption 5 are both predecisional and deliberative, and do not contain or represent formal or informal agency policies or decisions. Examples of information withheld include draft summaries.


Exemption 6 protects information in personnel and medical files and similar files when disclosure would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption 6 consists of personal information, such as names and email addresses. We have determined that the individuals to whom this information pertains has a substantial privacy interest in withholding it.

In accordance with the Department's implementing regulations, 45 CFR Part 5, no FOIA processing fees are due for request #20-00631-FOIA.

You may contact our FOIA Public Liaison at 770-488-6277 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. You may also transmit your appeal via email to FOIARequest@psc.hhs.gov. Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be postmarked or electronically transmitted by Monday, August 10, 2020.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized, cursive script.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
Phone: (770) 488-6399
Fax: (404) 235-1852

Enclosures

#20-00631-FOIA

From: Heininger, Ulrich
Sent: 29 Aug 2019 04:36:51 +0000
To: Admin;nkarora@incentrust.org;fombonne@ohsu.edu;nathalie.garcon@bioaster.org;jason.m.glanz@kp.org;nhalsey@jhspk.edu;All@ssi.dk;paul.lambert@unige.ch;heidi.larson@lshtm.ac.uk;Markowitz, Lauri (CDC/DDID/NCIRD/DVD);offit@email.chop.edu;Peden, Keith (FDA/CBER);andrew.pollard@paediatrics.ox.ac.uk;Sejvar, James (CDC/DDID/NCEZID/DHCPP);Zuber, Patrick (CDC who.int);Destefano, Frank (CDC/DDID/NCEZID/DHQP);kathryn.edwards@vumc.org;jim.buttery@monash.edu;(b)(6);(b)(6);amy@vaccinateyourfamily.org;dsalmon1@jhu.edu;m.c.j.sturkenboom@umcutrecht.nl;priya.bahri@ema.europa.eu;(b)(6);bodenstabh@email.chop.edu;(b)(6);(b)(6);hotez@bcm.edu;liz.miller@hpa.org.uk;h.petousis-harris@auckland.ac.nz;amyp@ecbt.org
Cc: 'Stanley Plotkin';Heininger, Ulrich
Subject: AW: Wellcome Trust - Summary of Ideas - Version 3
Attachments: London Ideas version 3_UH.docx

Dear Stanley and colleagues
thank you for the summary. I apologize for not having commented earlier, I was very busy with other projects but I followed the discussion.
Attached please find some critical - hopefully constructive - comments regarding the ideas that were brought forward.
I would be happy to be part of those projects that will be followed further on.

Best regards

Uli

(Ulrich Heininger)

Von: Admin <admin@vaxconsult.com>
Gesendet: Dienstag, 27. August 2019 21:02:39
An: nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhspk.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; lem2@cdc.gov; offit@email.chop.edu; keith.peden@fda.hhs.gov; andrew.pollard@paediatrics.ox.ac.uk; zea3@cdc.gov; zuberp@who.int; fxd1@cdc.gov; kathryn.edwards@vumc.org; jim.buttery@monash.edu;(b)(6) Heininger, Ulrich; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu;(b)(6) bodenstabh@email.chop.edu; (b)(6) hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org
Cc: 'Stanley Plotkin'
Betreff: Wellcome Trust - Summary of Ideas - Version 3

Dear Attendee at the London Vaccine Safety meeting:

I am sending again version 3 of ideas for new vaccine studies. The only comments I am aware of having received came from Frank Destefano, Nathalie Garcon and Helen Petousis-Harris. Before going ahead to a final revision I would appreciate your comments or at least your agreement with what is proposed.

The article summarizing the talks at the meeting is under review by the journal *Vaccine*.

Thanks,

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Stanley Plotkin [<mailto:stanley.plotkin@vaxconsult.com>]

Sent: Monday, August 12, 2019 9:37 AM

To: 'Admin'

Subject: send to london attendees

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to *Vaccine* today or tomorrow.

Stanley

From: Edwards, Kathryn
Sent: 19 Aug 2019 12:35:08 +0000
To: Helen Petousis-Harris; GARCON Nathalie; Destefano, Frank
(CDC/DDID/NCEZID/DHQP); Admin; jim.buttery@monash.edu; (b)(6); ulrich.hei
ninger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcut
recht.nl; priya.bahri@ema.europa.eu (b)(6); bodenstabh@email.chop.edu; (b)(6)
(b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; amyp@ecbt.org; nkarora@incitrust.or
g; fombonne@ohsu.edu; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@un
ige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri
(CDC/DDID/NCIRD/DVD); offit@email.chop.edu; Peden, Keith
(FDA/CBER); andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James
(CDC/DDID/NCEZID/DHCPP); Zuber, Patrick (CDC who.int)
Cc: stanley.plotkin@vaxconsult.com
Subject: Re: Updated Vaccine Safety Meeting Summary of Ideas

Helen

I would like to talk with you more about the POTS and CRPS definitions. I am very interested in this. We have an expert here at Vanderbilt in POTS and she has been working with CISA some to review the studies. Perhaps we can talk more when I come to New Zealand next month. k

From: Helen Petousis-Harris <h.petousis-harris@auckland.ac.nz>
Sent: Sunday, August 18, 2019 11:11 PM
To: GARCON Nathalie <Nathalie.GARCON@bioaster.org>; Destefano, Frank
(CDC/DDID/NCEZID/DHQP) <fxdl1@cdc.gov>; Admin <admin@vaxconsult.com>; Edwards,
Kathryn <kathryn.edwards@vumc.org>; jim.buttery@monash.edu <jim.buttery@monash.edu>;
(b)(6); ulrich.heininger@ukbb.ch
<ulrich.heininger@ukbb.ch>; amy@vaccinateyourfamily.org <amy@vaccinateyourfamily.org>;
dsalmon1@jhu.edu <dsalmon1@jhu.edu>; m.c.j.sturkenboom@umcutrecht.nl
<m.c.j.sturkenboom@umcutrecht.nl>; priya.bahri@ema.europa.eu
<priya.bahri@ema.europa.eu>; (b)(6)
bodenstabh@email.chop.edu <bodenstabh@email.chop.edu>; (b)(6)
(b)(6); hotez@bcm.edu <hotez@bcm.edu>; liz.miller@hpa.org.uk
<liz.miller@hpa.org.uk>; amyp@ecbt.org <amyp@ecbt.org>; nkarora@incitrust.org
<nkarora@incitrust.org>; fombonne@ohsu.edu <fombonne@ohsu.edu>;
jason.m.glanz@kp.org <jason.m.glanz@kp.org>; nhalsey@jhsph.edu <nhalsey@jhsph.edu>;
All@ssi.dk <All@ssi.dk>; paul.lambert@unige.ch <paul.lambert@unige.ch>;
heidi.larson@lshtm.ac.uk <heidi.larson@lshtm.ac.uk>; Markowitz, Lauri
(CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu <offit@email.chop.edu>;
Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk
<andrew.pollard@paediatrics.ox.ac.uk>; Sejvar, James (CDC/DDID/NCEZID/DHCPP)
<zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com <stanley.plotkin@vaxconsult.com>
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

A couple more thoughts from me on top of Frank and Nathalie's

Kind regards
helen

From: GARCON Nathalie <Nathalie.GARCON@bioaster.org>
Sent: Friday, 16 August 2019 8:08 PM
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>; Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; Helen Petousis-Harris <h.petousis-harris@auckland.ac.nz>; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Dear all

All my apologize for the late answers
Some personal matters took me away for the past 2 months

Cheers

nathalie

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Thursday, August 15, 2019 4:47 PM
To: Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; rtchen1135@gmail.com; ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; GARCON Nathalie <Nathalie.GARCON@bioaster.org>; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Attached are my comments.

Thanks,
Frank

Frank DeStefano, MD, MPH

From: Admin <admin@vaxconsult.com>
Sent: Monday, August 12, 2019 11:16 AM
To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6)
ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu;
m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6)
bodenstabh@email.chop.edu; (b)(6) hotez@bcm.edu; liz.miller@hpa.org.uk;
h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@inclentrust.org;
fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org;
nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz,
Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith
(FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James
(CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>;
Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Cc: stanley.plotkin@vaxconsult.com
Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Helen Petousis-Harris
Sent: 19 Aug 2019 04:11:39 +0000
To: GARCON Nathalie; Destefano, Frank
(CDC/DDID/NCEZID/DHQP); Admin; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6)
(b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6)
(b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD); offit@email.chop.edu; Peden, Keith (FDA/CBER); andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP); Zuber, Patrick (CDC who.int)
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas
Attachments: London Ideas version 3 fxdhph.docx

A couple more thoughts from me on top of Frank and Nathalie's

Kind regards
helen

From: GARCON Nathalie <Nathalie.GARCON@bioaster.org>
Sent: Friday, 16 August 2019 8:08 PM
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>; Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6)
ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu;
m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6)
bodenstabh@email.chop.edu; (b)(6) hotez@bcm.edu; liz.miller@hpa.org.uk; Helen Petousis-Harris <h.petousis-harris@auckland.ac.nz>; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Dear all

All my apologize for the late answers
Some personal matters took me away for the past 2 months

Cheers

nathalie

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Thursday, August 15, 2019 4:47 PM

To: Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6) <(b)(6)>; ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6) <(b)(6)>; bodenstabh@email.chop.edu; (b)(6) <(b)(6)>; hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@inclentrust.org; fombonne@ohsu.edu; GARCON Nathalie <Nathalie.GARCON@bioaster.org>; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Attached are my comments.

Thanks,

Frank

Frank DeStefano, MD, MPH

From: Admin <admin@vaxconsult.com>
Sent: Monday, August 12, 2019 11:16 AM
To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6) <(b)(6)>; ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6) <(b)(6)>; bodenstabh@email.chop.edu; (b)(6) <(b)(6)>; hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@inclentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>; Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Cc: stanley.plotkin@vaxconsult.com
Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Sent: 16 Aug 2019 13:12:06 +0000
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP)
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Thanks for sending in those comments. Agree with all.

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Thursday, August 15, 2019 10:47 AM
To: Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Attached are my comments.

Thanks,
Frank

Frank DeStefano, MD, MPH

From: Admin <admin@vaxconsult.com>
Sent: Monday, August 12, 2019 11:16 AM
To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>; Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Cc: stanley.plotkin@vaxconsult.com
Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: GARCON Nathalie
Sent: 16 Aug 2019 08:08:29 +0000
To: Destefano, Frank
(CDC/DDID/NCEZID/DHQP);Admin;kathryn.edwards@vumc.org;jim.buttery@monash.edu;(b)(6);ulrich.heininger@ukbb.ch;amy@vaccinateyourfamily.org;dsalmon1@jhu.edu;m.c.j.sturkenboom@umcutrecht.nl;priya.bahri@ema.europa.eu;(b)(6);bodenstabh@email.chop.edu;al;(b)(6);hotez@bcm.edu;liz.miller@hpa.org.uk;h.petousis-harris@auckland.ac.nz;amyp@ecbt.org;nkarora@incitrust.org;fombonne@ohsu.edu;jason.m.glanz@kp.org;nhalsey@jhsph.edu;All@ssi.dk;paul.lambert@unige.ch;heidi.larson@lshtm.ac.uk;Markowitz, Lauri (CDC/DDID/NCIRD/DVD);offit@email.chop.edu;Peden, Keith (FDA/CBER);andrew.pollard@paediatrics.ox.ac.uk;Sejvar, James (CDC/DDID/NCEZID/DHCPP);Zuber, Patrick (CDC who.int)
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas
Attachments: London Ideas version 3 fxd.docx

Dear all

All my apologize for the late answers
Some personal matters took me away for the past 2 months

Cheers

nathalie

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Thursday, August 15, 2019 4:47 PM
To: Admin <admin@vaxconsult.com>; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@incitrust.org; fombonne@ohsu.edu; GARCON Nathalie <Nathalie.GARCON@bioaster.org>; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>
Cc: stanley.plotkin@vaxconsult.com
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Attached are my comments.

Thanks,
Frank

Frank DeStefano, MD, MPH

From: Admin <admin@vaxconsult.com>

Sent: Monday, August 12, 2019 11:16 AM

To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>; Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>

Cc: stanley.plotkin@vaxconsult.com

Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Sejvar, James (CDC/DDID/NCEZID/DHCPP)
Sent: 12 Aug 2019 20:59:16 +0000
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP); Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Hi Frank,
I, James J. Sejvar, approve the document to be submitted to CDC clearance.

Just let me know if you need anything else.

Thanks,
Jim

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Monday, August 12, 2019 2:17 PM
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Jim,
I will be putting the manuscript into CDC clearance. Since you are a co-author, could you send me a message that you approve of the article.
Thanks,
Frank

Frank DeStefano, MD, MPH

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Monday, August 12, 2019 1:50 PM
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

Hi Frank,

I hope you has a good vacation - I know it is hard coming back after 2 weeks!

There were some errors in the HPV section still - with refs – that they were fixing. Maybe you need to let Stanley know it needs to go through CDC clearance and ask for a clean copy. Sounds like not all have reviewed yet?

Lauri

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Monday, August 12, 2019 12:30 PM
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

I've been on leave the past two weeks and kind of lost track of this. I guess I need an email from you saying that you agree to be a co-author.

Thanks,
Frank

Frank DeStefano, MD, MPH

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Monday, August 12, 2019 11:23 AM
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Subject: FW: Updated Vaccine Safety Meeting Summary of Ideas

"The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow."

Do you need to put this through CDC clearance first?

From: Admin <admin@vaxconsult.com>
Sent: Monday, August 12, 2019 11:16 AM
To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6);
ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu;
m.c.j.sturkenboom@umcutrecht.nl; priva.bahri@ema.europa.eu; (b)(6);
bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk;
h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@inclentrust.org; fombonne@ohsu.edu;
nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk;
paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
<lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>;
andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>;
Zuber, Patrick (CDC who.int) <zuberp@who.int>; Destefano, Frank (CDC/DDID/NCEZID/DHQP)
<fxd1@cdc.gov>
Cc: stanley.plotkin@vaxconsult.com
Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD)
Sent: 12 Aug 2019 19:30:24 +0000
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP)
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

I agree with submitting "The Science of Vaccine Safety: Summary of Meeting at Wellcome Trust" to CDC clearance.

Lauri Markowitz, MD

*Viral Vaccine Preventable Diseases Branch/Division of Viral Diseases
Associate Director of Science for HPV
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Rd MS H24-5
Atlanta, GA 30329-4027
Phone: 404-639-8359
Email: lem2@cdc.gov*

From: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Sent: Monday, August 12, 2019 12:30 PM
To: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Subject: RE: Updated Vaccine Safety Meeting Summary of Ideas

I've been on leave the past two weeks and kind of lost track of this. I guess I need an email from you saying that you agree to be a co-author.

Thanks,
Frank

Frank DeStefano, MD, MPH

From: Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>
Sent: Monday, August 12, 2019 11:23 AM
To: Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>
Subject: FW: Updated Vaccine Safety Meeting Summary of Ideas

"The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow."

Do you need to put this through CDC clearance first?

From: Admin <admin@vaxconsult.com>
Sent: Monday, August 12, 2019 11:16 AM
To: kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6);
ulrich.heininger@ukbb.ch; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu;
m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6);
bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk;

h.petousis-harris@auckland.ac.nz; amyp@ecbt.org; nkarora@inclentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD) <lem2@cdc.gov>; offit@email.chop.edu; Peden, Keith (FDA/CBER) <Keith.Peden@fda.hhs.gov>; andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP) <zea3@cdc.gov>; Zuber, Patrick (CDC who.int) <zuberp@who.int>; Destefano, Frank (CDC/DDID/NCEZID/DHQP) <fxd1@cdc.gov>

Cc: stanley.plotkin@vaxconsult.com

Subject: Updated Vaccine Safety Meeting Summary of Ideas

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Stanley Plotkin
Sent: 30 Aug 2019 08:47:33 -0400
To: 'Amy
Pisani'; 'Admin'; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhspk.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD); offit@email.chop.edu; Peden, Keith (FDA/CBER); andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP); Zuber, Patrick (CDC who.int); Destefano, Frank (CDC/DDID/NCEZID/DHQP); kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6) om; ulrich.heininger@ukbb.ch; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz
Subject: RE: Wellcome Trust - Summary of Ideas - Version 3

Dear Amy:

This is very good news and I congratulate you on your efforts. A summary of the London meeting has been sent to Vaccine hopefully for publication, and I am trying to get a final version of ideas for safety studies to carry forward to funders. It is a pleasure to work with you.

Stanley

From: Amy Pisani [mailto:amy@vaccinateyourfamily.org]
Sent: Friday, August 30, 2019 8:35 AM
To: Admin; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhspk.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; lem2@cdc.gov; offit@email.chop.edu; keith.peden@fda.hhs.gov; andrew.pollard@paediatrics.ox.ac.uk; zea3@cdc.gov; zuberp@who.int; fxd1@cdc.gov; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz
Cc: 'Stanley Plotkin'
Subject: RE: Wellcome Trust - Summary of Ideas - Version 3

I wanted to let this group know how much the presentations have been of service to Vaccinate Your Family over the past couple of months (as well as this ongoing dialogue). I downloaded them all and kept them confidential while also working to incorporate numerous new answers to frequently asked questions on our website. Several of the presentations have also been instrumental in helping answer the many questions that are sent to our organization via Facebook and direct email. We are planning to comb through CHOPs research database in the coming months to enhance our Research Section... Thank you all from the bottom of my heart.

I also wanted to alert you to an initiative that we have been taking part in here in the U.S. which was started by several Fellows at Ted.com. This collaborative includes representatives from WHO, Sabin, VYF, CDC and other NGOs as well as representatives from all of the major social media companies (Twitter, Pinterest, Facebook/Instagram, Google and YouTube). We are working together to identify the false information shared online (which we call zombie rumors, since they never die) and determine where there are gaps in knowledge and how to improve the "fact checkers" ability to weed out disinformation and elevate science driven information, thereby increasing the likelihood of those seeking information based on keywords to be sent to credible sources.

On Wednesday Pinterest made a formal announcement (see below) and I'm proud to say that VYF has been essential to this effort: Ifeoma Ozoma, Public Policy and Social Impact Manager who is leading this initiative at Pinterest is part of the Ted collaborative that my staff and I have been serving on. Our input regarding the serious impact that disinformation is having on the global confidence in vaccines truly resonated with those who attended. Ifeoma was very engaged at the meeting in NY in June and I'm not at all surprised to see Pinterest be the first to take this step. The Google, Twitter, YouTube, FB/Instagram execs are also part of the ongoing "collaborative" and I suspect/hope they will use the same criteria. The good news for IAC, CHOP, Vaccinate Your Family and others is that we are all members of the Vaccine Safety Net!

Have a wonderful weekend.


Amy Pisani, MS
Executive Director
(202) 277-7587



<https://newsroom.pinterest.com/en/post/bringing-authoritative-vaccine-results-to-pinterest-search>

More than 300 million people come to Pinterest every month to get inspired and find ideas, from easy weeknight meals to crafts to do with kids. We believe a healthy life is an inspired life, and today we have an update on our efforts to combat health misinformation.

We're introducing a new experience for vaccine-related searches on Pinterest. Now, when you search for "measles," "vaccine safety" and other related health terms, you can explore reliable results about immunizations from leading public health organizations, including the World Health Organization (WHO), the Centers for Disease Control (CDC), the American Academy of Pediatrics (AAP) and the WHO-established Vaccine Safety Net (VSN), a global network of websites providing reliable vaccine safety information in various languages.



Last year, we made the decision to stop showing results for searches related to vaccines as a way to prevent people from encountering harmful health misinformation. This new search experience only shows content from leading public health institutions—you won't see any recommendations or comments on Pins in these results. We also won't show ads. We're taking this approach because we believe that showing vaccine misinformation alongside resources from public health experts isn't responsible.

As we continue to tackle health misinformation, we remove it and the accounts that spread it from our service. But we also want to bring expert content onto Pinterest. We know we aren't medical experts, which is why we're working with professionals to inspire Pinner with reliable information about health.

With these authoritative Pins now in our system, they can also be discovered in home feed, related Pins and from the profiles of the [WHO](#), [VSN](#), [CDC](#) and [AAP](#).

Health misinformation is contagious

Hesitancy around vaccines is one of this year's top global health threats, according to the [WHO](#). In addition, the [CDC](#) confirmed that the U.S. is experiencing the greatest number of measles cases reported since 1992 and since the virus was declared eliminated in 2000.

Since 2017 it's been against our [community guidelines](#) to promote anti-vaccination advice and other health misinformation, and we've never allowed it to be advertised. We've long used guidance from these health institutions to inform our policy and how we enforce it, but we wanted to do more.

Here's why.


Health misinformation has the potential to impact public health, regardless of what service it's found on. Allowing this content to spread through Pinterest's search results is not in line with enforcing our community guidelines. That's why we're limiting search results to internationally recognized health organizations.

What we and others have observed is an enthusiasm gap between those creating and disseminating harmful health misinformation and those creating resources rooted in settled science. Generally, there's more accessible and visually compelling health misinformation than science-based journal articles on the virtues of vaccinations. In addition, we've found that some purveyors of health misinformation have a financial incentive. For instance, some sell products and potions, and others use spammer tactics and clickbait to drive traffic to their own sites where they monetize.

On top of that, [experts](#) have shown there's a [data void](#) when it comes to reliable information about vaccines—there's a greater distribution of vaccine misinformation than information. In short, anti-vaccine content is contagious.

As another way to address that gap, we're developing creative resources that health organizations can easily use to create visually compelling Pins for

content that's primarily text-based. For example, below is a Pin the AAP created with the help of our creative team.



The work continues

We're starting with vaccinations because the WHO determined that vaccine hesitancy is a significant threat to everyone. We'll need to keep evolving our list of terms for which we block medical misinformation and provide expert advice as people try to get around our safeguards. We'll also continue to remove this content and accounts that spread it from our service.

This new search experience is now available globally in English on the web and in our mobile apps for iPhone and Android. We look forward to continuing our work with health experts to expand authoritative results on other searches and in more languages.

Ultimately, we want to bring authoritative results to more Pinner in more places, because there's nothing inspiring about harmful health misinformation.

- Ifeoma Ozoma, Public Policy and Social Impact Manager

From: Admin <admin@vaxconsult.com>

Sent: Tuesday, August 27, 2019 3:03 PM

To: nkarora@incenttrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; All@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; lem2@cdc.gov; offit@email.chop.edu; keith.peden@fda.hhs.gov; andrew.pollard@paediatrics.ox.ac.uk; zea3@cdc.gov; zuberp@who.int; fxd1@cdc.gov; kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); ulrich.heininger@ukbb.ch; Amy Pisani <amy@vaccinateyourfamily.org>; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; Amy Pisani <amy@vaccinateyourfamily.org>

Cc: 'Stanley Plotkin' <stanley.plotkin@vaxconsult.com>

Subject: Wellcome Trust - Summary of Ideas - Version 3

Dear Attendee at the London Vaccine Safety meeting:

I am sending again version 3 of ideas for new vaccine studies. The only comments I am aware of having received came from Frank Destefano, Nathalie Garcon and Helen Petousis-Harris. Before going ahead to a final revision I would appreciate your comments or at least your agreement with what is proposed.

The article summarizing the talks at the meeting is under review by the journal *Vaccine*.

Thanks,

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Stanley Plotkin [<mailto:stanley.plotkin@vaxconsult.com>]

Sent: Monday, August 12, 2019 9:37 AM

To: 'Admin'

Subject: send to london attendees

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

From: Paul Henri Lambert
Sent: 29 Aug 2019 10:01:02 +0000
To: Heininger, Ulrich; Admin; nkarora@incentrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhspk.edu; All@ssi.dk; heidi.larson@lshtm.ac.uk; Markowitz, Lauri (CDC/DDID/NCIRD/DVD); offit@email.chop.edu; Peden, Keith (FDA/CBER); andrew.pollard@paediatrics.ox.ac.uk; Sejvar, James (CDC/DDID/NCEZID/DHCPP); Zuber, Patrick (CDC who.int); Destefano, Frank (CDC/DDID/NCEZID/DHQP); kathryn.edwards@vumc.org; jim.buttery@monash.edu; (b)(6); amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; (b)(6); bodenstabh@email.chop.edu; (b)(6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org
Cc: 'Stanley Plotkin'; Heininger, Ulrich
Subject: RE: Wellcome Trust - Summary of Ideas - Version 3

Dear Stanley,

I would add a paragraph on the need to promote research on the assessment of the risk of infectious disease enhancement after vaccination, particularly with non-optimal vaccines (e.g. Dengue, RSV, influenza)

Besides, I think that it would be beneficial if these various ideas would be integrated in a more comprehensive document with more structured sections.

Best regards

Paul-Henri

Provenance : [Courrier](#) pour Windows 10

De : [Heininger, Ulrich](#)

Envoyé le : jeudi, 29 août 2019 06:37

À : [Admin](#); [nkarora@incentrust.org](#); [fombonne@ohsu.edu](#); [nathalie.garcon@bioaster.org](#); [jason.m.glanz@kp.org](#); [nhalsey@jhspk.edu](#); [All@ssi.dk](#); [Paul Henri Lambert](#); [heidi.larson@lshtm.ac.uk](#); [lem2@cdc.gov](#); [offit@email.chop.edu](#); [keith.peden@fda.hhs.gov](#); [andrew.pollard@paediatrics.ox.ac.uk](#); [zea3@cdc.gov](#); [zuberp@who.int](#); [fxd1@cdc.gov](#); [kathryn.edwards@vumc.org](#); [jim.buttery@monash.edu](#); (b)(6); [amy@vaccinateyourfamily.org](#); [dsalmon1@jhu.edu](#); [m.c.j.sturkenboom@umcutrecht.nl](#); [priya.bahri@ema.europa.eu](#); (b)(6); [bodenstabh@email.chop.edu](#); (b)(6); [hotez@bcm.edu](#); [liz.miller@hpa.org.uk](#); [h.petousis-harris@auckland.ac.nz](#); [amyp@ecbt.org](#)

Cc : 'Stanley Plotkin'; [Heininger, Ulrich](#)

Objet : AW: Wellcome Trust - Summary of Ideas - Version 3

Dear Stanley and colleagues

thank you for the summary. I apologize for not having commented earlier, I was very busy with other projects but I followed the discussion.

Attached please find some critical - hopefully constructive - comments regarding the ideas that were brought forward.

I would be happy to be part of those projects that will be followed further on.

Best regards

Uli

(Ulrich Heininger)

Von: Admin <admin@vaxconsult.com>

Gesendet: Dienstag, 27. August 2019 21:02:39

An: nkarora@inclustrust.org; fombonne@ohsu.edu; nathalie.garcon@bioaster.org; jason.m.glanz@kp.org; nhalsey@jhsph.edu; AII@ssi.dk; paul.lambert@unige.ch; heidi.larson@lshtm.ac.uk; lem2@cdc.gov; offit@email.chop.edu; keith.peden@fda.hhs.gov; andrew.pollard@paediatrics.ox.ac.uk; zea3@cdc.gov; zuberp@who.int; fxd1@cdc.gov; kathryn.edwards@vumc.org; jim.buttery@monash.edu; [b](6); Heininger, Ulrich; amy@vaccinateyourfamily.org; dsalmon1@jhu.edu; m.c.j.sturkenboom@umcutrecht.nl; priya.bahri@ema.europa.eu; [b](6); bodenstabh@email.chop.edu; [b](6); hotez@bcm.edu; liz.miller@hpa.org.uk; h.petousis-harris@auckland.ac.nz; amyp@ecbt.org

Cc: 'Stanley Plotkin'

Betreff: Wellcome Trust - Summary of Ideas - Version 3

Dear Attendee at the London Vaccine Safety meeting:

I am sending again version 3 of ideas for new vaccine studies. The only comments I am aware of having received came from Frank Destefano, Nathalie Garcon and Helen Petousis-Harris. Before going ahead to a final revision I would appreciate your comments or at least your agreement with what is proposed.

The article summarizing the talks at the meeting is under review by the journal *Vaccine*.

Thanks,

Stanley

[b](6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Stanley Plotkin [<mailto:stanley.plotkin@vaxconsult.com>]

Sent: Monday, August 12, 2019 9:37 AM

To: 'Admin'

Subject: send to london attendees

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

From: Admin
Sent: 12 Aug 2019 11:16:20 -0400
To: kathryn.edwards@vumc.org;jim.buttery@monash.edu;(b)(6);ulrich.heininger@ukbb.ch;amy@vaccinateyourfamily.org;dsalmon1@jhu.edu;m.c.j.sturkenboom@umcutrecht.nl;priya.bahri@ema.europa.eu;(b)(6);bodenstabh@email.chop.edu;(b)(6);hotez@bcm.edu;liz.miller@hpa.org.uk;h.petousis-harris@auckland.ac.nz;amyp@ecbt.org;nkarora@incitrust.org;fombonne@ohsu.edu;nathalie.garcon@bioaster.org;jason.m.glanz@kp.org;nhalsey@jhsph.edu;All@ssi.dk;paul.lambert@unige.ch;heidi.larson@lshtm.ac.uk;Markowitz, Lauri (CDC/DDID/NCIRD/DVD);offit@email.chop.edu;Peden, Keith (FDA/CBER);andrew.pollard@paediatrics.ox.ac.uk;Sejvar, James (CDC/DDID/NCEZID/DHCPP);Zuber, Patrick (CDC who.int);Destefano, Frank (CDC/DDID/NCEZID/DHQP)
Cc: stanley.plotkin@vaxconsult.com
Subject: Updated Vaccine Safety Meeting Summary of Ideas
Attachments: London Ideas version 3.docx

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to Vaccine today or tomorrow.

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

SUMMARY OF IDEAS FOR FUTURE STUDIES PROPOSED BY ATTENDEES AT THE WELLCOME TRUST LONDON VACCINE SAFETY MEETING (Version 3, Aug 10/19)

Specific Reactions

There is no recent study of whole cell pertussis vaccine safety. Inasmuch as large parts of the world are still using WcP, a study could be done in one of those countries, although admittedly one would have to carefully choose the vaccine being studied and the sample size needed.

Autoimmune disease after vaccination is frequently alleged based on the appearance of autoimmune antibodies. A feasible study would be to compare the appearance of autoimmune antibodies in adolescents immunized with HPV and a similar population of adolescents who did not receive HPV.

Badly needed is a controlled study in adolescents of POTS and CRPS syndromes. Does vaccination increase the risk?

Together with increased studies of narcolepsy in animal models, more study of the genetics of narcolepsy is needed, which could be done in Nordic countries where narcolepsy is more common.

Denmark provides an excellent country in which to do comparative studies in view of specimen availability and investigator interest. Dried blood spots have been collected since 1982. At least three phenomena could be studied given enough financial support: GWAS analyses of febrile seizures after vaccination, Guillain-Barré syndrome after influenza vaccine, and idiopathic thrombocytic purpura (ITP) after MMR vaccine.

Maternal Immunization

It is critical to study what is now a widespread recommended vaccination strategy with respect to the outcome in infants born to vaccinated mothers. Large cohorts will be needed in which infants of vaccinated and unvaccinated mothers are followed for at least several years with regard to health phenomena. Among the outcomes studied would be autism, other neurological phenomena, time of vaccination in the mother, and time of first vaccine in the child.

Adjuvants and Preservatives

Again, advantage could be taken of the Danish population to study granulomas following the use of aluminum adjuvants, as granulomas appear to have a familial tendency. Predisposing factors, including genetics through GWAS, could be studied, as well as rates of autism in relation to quantity of aluminum received.

Another study that could be done in Denmark involves a follow up of vaccinees to determine if tics are really associated with mercury content received. This is important as the CDC study raised questions.

Advantage could be taken of the fact that there is twice as much of aluminum adjuvant in the 9 valent HPV vaccine as the 4 valent HPV vaccine (500 vs 250 mcg). Long term health phenomena could be compared.

The new zoster vaccine and one influenza vaccine both have strong adjuvants. No study has looked at patients who receive both simultaneously.

Although there would be difficulties in analyzing equivalent populations, the fact that certain adjuvants are used in Europe but not the US might serve as a basis for a study.

A discussion with manufacturers is warranted to see if multi-dose vials could be eliminated, which would reduce the need for preservatives in vaccines.

Genetics

Aside from the studies mentioned above, a registry of reactions to vaccines in patients with mitochondrial or metabolic diseases would help determine contra-indications if any.

Other

Create a DNA biobank of samples from vaccinees with adverse reactions. Admittedly this might be difficult owing to concerns about storage, privacy, etc.

If possible, compare reactions in children given vaccines individually or in combination.

Do a follow-up study of patients who developed measles during the current outbreak to determine rate of sequelae.

More publications are needed on the subject of vaccine safety. For example, using US data to calculate rate of reactions with regard to number of doses given, safety reviews concerning individual vaccines, particularly HPV.

The CISA network is in operation but is not sufficiently used. Appeals could be made to medical specialists to report patients for study at CISA. In addition, a repository for information on vaccination in patients with mitochondrial diseases would be helpful.

A frequent recommendation was that the US tax on vaccines be used to finance safety studies. This would require congressional action. Moreover, a vaccine safety agenda using such monies was proposed by NVAC in the late 1990s, but nothing has happened.

From: Admin
Sent: 27 Aug 2019 15:02:39 -0400
To: nkarora@incentrtrust.org;fombonne@ohsu.edu;nathalie.garcon@bioaster.org;jason.m.glanz@kp.org;nhalsey@jhsph.edu;All@ssi.dk;paul.lambert@unige.ch;heidi.larson@lshtm.ac.uk;Markowitz, Lauri (CDC/DDID/NCIRD/DVD);offit@email.chop.edu;Peden, Keith (FDA/CBER);andrew.pollard@paediatrics.ox.ac.uk;Sejvar, James (CDC/DDID/NCEZID/DHCPP);Zuber, Patrick (CDC who.int);Destefano, Frank (CDC/DDID/NCEZID/DHQP);kathryn.edwards@vumc.org;jim.buttery@monash.edu;(b)(6);ulrich.heininger@ukbb.ch;amy@vaccinateyourfamily.org;dsalmon1@jhu.edu;m.c.j.sturkenboom@umcutrecht.nl;priya.bahri@ema.europa.eu;(b)(6);bodenstabh@email.chop.edu;(b)(6);(b)(6);hotez@bcm.edu;liz.miller@hpa.org.uk;h.petousis-harris@auckland.ac.nz;amyp@ecbt.org
Cc: 'Stanley Plotkin'
Subject: Wellcome Trust - Summary of Ideas - Version 3
Attachments: London Ideas version 3.docx

Dear Attendee at the London Vaccine Safety meeting:

I am sending again version 3 of ideas for new vaccine studies. The only comments I am aware of having received came from Frank Destefano, Nathalie Garcon and Helen Petousis-Harris. Before going ahead to a final revision I would appreciate your comments or at least your agreement with what is proposed.

The article summarizing the talks at the meeting is under review by the journal *Vaccine*.

Thanks,

Stanley

(b)(6)

Assistant to Dr. Stanley Plotkin
4650 Wismer Road
Doylestown, PA 18902
215-297-9321

From: Stanley Plotkin [<mailto:stanley.plotkin@vaxconsult.com>]
Sent: Monday, August 12, 2019 9:37 AM
To: 'Admin'
Subject: send to london attendees

Dear Attendee at the London Vaccine Safety meeting:

This is an updated version of the summary of ideas. Please review and comment as I plan to use this to start discussions with funders.

The article summarizing the talks at the meeting will be submitted to *Vaccine* today or tomorrow.

Stanley

SUMMARY OF IDEAS FOR FUTURE STUDIES PROPOSED BY ATTENDEES AT THE WELLCOME TRUST LONDON VACCINE SAFETY MEETING (Version 3, Aug 10/19)

Specific Reactions

There is no recent study of whole cell pertussis vaccine safety. Inasmuch as large parts of the world are still using WcP, a study could be done in one of those countries, although admittedly one would have to carefully choose the vaccine being studied and the sample size needed.

Autoimmune disease after vaccination is frequently alleged based on the appearance of autoimmune antibodies. A feasible study would be to compare the appearance of autoimmune antibodies in adolescents immunized with HPV and a similar population of adolescents who did not receive HPV.

Badly needed is a controlled study in adolescents of POTS and CRPS syndromes. Does vaccination increase the risk?

Together with increased studies of narcolepsy in animal models, more study of the genetics of narcolepsy is needed, which could be done in Nordic countries where narcolepsy is more common.

Denmark provides an excellent country in which to do comparative studies in view of specimen availability and investigator interest. Dried blood spots have been collected since 1982. At least three phenomena could be studied given enough financial support: GWAS analyses of febrile seizures after vaccination, Guillain-Barré syndrome after influenza vaccine, and idiopathic thrombocytic purpura (ITP) after MMR vaccine.

Maternal Immunization

It is critical to study what is now a widespread recommended vaccination strategy with respect to the outcome in infants born to vaccinated mothers. Large cohorts will be needed in which infants of vaccinated and unvaccinated mothers are followed for at least several years with regard to health phenomena. Among the outcomes studied would be autism, other neurological phenomena, time of vaccination in the mother, and time of first vaccine in the child.

Adjuvants and Preservatives

Again, advantage could be taken of the Danish population to study granulomas following the use of aluminum adjuvants, as granulomas appear to have a familial tendency. Predisposing factors, including genetics through GWAS, could be studied, as well as rates of autism in relation to quantity of aluminum received.

Another study that could be done in Denmark involves a follow up of vaccinees to determine if tics are really associated with mercury content received. This is important as the CDC study raised questions.

Advantage could be taken of the fact that there is twice as much of aluminum adjuvant in the 9 valent HPV vaccine as the 4 valent HPV vaccine (500 vs 250 mcg). Long term health phenomena could be compared.

The new zoster vaccine and one influenza vaccine both have strong adjuvants. No study has looked at patients who receive both simultaneously.

Although there would be difficulties in analyzing equivalent populations, the fact that certain adjuvants are used in Europe but not the US might serve as a basis for a study.

A discussion with manufacturers is warranted to see if multi-dose vials could be eliminated, which would reduce the need for preservatives in vaccines.

Genetics

Aside from the studies mentioned above, a registry of reactions to vaccines in patients with mitochondrial or metabolic diseases would help determine contra-indications if any.

Other

Create a DNA biobank of samples from vaccinees with adverse reactions. Admittedly this might be difficult owing to concerns about storage, privacy, etc.

If possible, compare reactions in children given vaccines individually or in combination.

Do a follow-up study of patients who developed measles during the current outbreak to determine rate of sequelae.

More publications are needed on the subject of vaccine safety. For example, using US data to calculate rate of reactions with regard to number of doses given, safety reviews concerning individual vaccines, particularly HPV.

The CISA network is in operation but is not sufficiently used. Appeals could be made to medical specialists to report patients for study at CISA. In addition, a repository for information on vaccination in patients with mitochondrial diseases would be helpful.

A frequent recommendation was that the US tax on vaccines be used to finance safety studies. This would require congressional action. Moreover, a vaccine safety agenda using such monies was proposed by NVAC in the late 1990s, but nothing has happened.